CurrentCignaPolicy N/A

Chelating Agents - Iron Chelators (Oral) Preferred Specialty Management Policy

Defines Cigna's preferred specialty management and non-preferred product exception criteria for oral iron chelators (deferasirox and deferiprone formulations) for members covered by Cigna benefit plans.

Policy Summary

PayerCigna

PolicyChelating Agents - Iron Chelators (Oral) Preferred Specialty Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateFeb 5, 2025

Key ActionSubmit prior authorization and documentation showing the patient meets the prior authorization criteria and step-therapy requirements to request an exception for non-preferred products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Preferred & Non-PreferredProduct categories

1 yearStandard approval

4Manufacturer references

Coverage Criteria for Non-Preferred Oral Iron Chelators

Non-Preferred Product Exception Criteria

Non-preferred products are covered as medically necessary when the following exception criteria are met

Policy Summary

PayerCigna

PolicyChelating Agents - Iron Chelators (Oral) Preferred Specialty Management Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review DateFeb 5, 2025

Key ActionSubmit prior authorization and documentation showing the patient meets the prior authorization criteria and step-therapy requirements to request an exception for non-preferred products.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Non-Preferred Product Exception (Exjade, Ferriprox tablets, Jadenu, Jadenu Sprinkle)

A: Patient meets the standard Chelating Agents - Iron Chelators (Oral) Prior Authorization Policy criteria
B: Patient has tried at least one preferred product: generic deferasirox tablets, generic deferasirox tablets for suspension, generic deferasirox granules, or generic deferiprone tablets

Non-Preferred Product Exception (Ferriprox oral solution)

A: Patient meets the standard Chelating Agents - Iron Chelators (Oral) Prior Authorization Policy criteria
B
- i: Patient has tried at least one preferred product: generic deferasirox tablets, generic deferasirox tablets for suspension, generic deferasirox granules, or generic deferiprone tablets
- ii: The dose prescribed cannot be attained with deferiprone tablets
- iii: Patient cannot swallow or has difficulty swallowing deferiprone tablets

Provider Requirements, Prior Authorization, and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior authorization is required per the standard Chelating Agents - Iron Chelators (Oral) Prior Authorization Policy. All requests (preferred and non-preferred) must meet that policy's criteria.

All approvals are provided for the duration noted in the prior authorization policy.
Requests for non-preferred products will be reviewed using the non-preferred product exception criteria.

Step Therapy

Step Therapy Requirement

Patients must try at least one Preferred Product before a Non-Preferred Product will be approved. This step therapy requirement applies to all non-preferred oral iron chelators listed in the policy.

Preferred products include: generic deferasirox tablets, generic deferasirox tablets for suspension, generic deferasirox granules, generic deferiprone tablets.
Non-preferred products (subject to step therapy) include: Exjade, Ferriprox (tablets and oral solution), Jadenu, Jadenu Sprinkle.

Documentation Required

Required Documentation

Providers must submit documentation demonstrating the member meets the terms of the plan and the applicable policy criteria, including evidence of prior trial of preferred product(s) when required and any information needed to apply exception criteria.

Include clinical rationale, prior authorization documentation, medication history showing trials of preferred products, dosing information, and swallowing/dosage-form limitations when relevant.

Denial Risk

Denial Triggers

Claims or authorization requests that do not include a covered diagnosis/procedure code or that fail to meet the plan's prior authorization, step therapy, or exception criteria will be denied.

Requests for non-preferred products that do not meet the listed exception criteria will be denied as not medically necessary.
When billing, providers must use the most appropriate codes as of the date of service; claims submitted without covered code(s) under the applicable coverage policy will be denied.

Background on Oral Iron Chelators

Oral iron chelators in this policy include deferasirox formulations (Exjade, Jadenu and generics) and deferiprone formulations (Ferriprox and generics). These agents are indicated for treatment of chronic/transfusional iron overload in affected patient populations; formulations and age/indication specifics differ by product. The program distinguishes Preferred Products (generic deferasirox tablets, generic deferasirox tablets for suspension, generic deferasirox granules, generic deferiprone tablets) from Non-Preferred Products (Exjade, Ferriprox tablets and oral solution, Jadenu, Jadenu Sprinkle) and applies prior authorization plus exception criteria for non-preferred product approval.

Drug Definitions and Indications

Deferasirox — product indications and summary

Active ingredient and formulationsDeferasirox — same chemical entity in Exjade and Jadenu formulations (tablets, granules, sprinkle) and generics

Primary indicationsChronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients ≥ 2 years of age

Non‑transfusion‑dependent thalassemia indicationChronic iron overload in non‑transfusion‑dependent thalassemia for patients ≥ 10 years with LIC ≥ 5 mg/g dry weight AND serum ferritin > 300 mcg/L

Limitation of useSafety and efficacy when administered with other iron chelation therapy have not been established

Deferiprone — product indications and summary

Product and formulationsDeferiprone (Ferriprox) available as tablets and oral solution (generics available)

Indications for tabletsTransfusional iron overload with thalassemia syndromes, sickle cell disease, or other anemias in patients ≥ 8 years of age

Indications for oral solutionTransfusional iron overload with thalassemia syndromes, sickle cell disease, or other anemias in patients ≥ 3 years of age

Limitation of useSafety and effectiveness not established for transfusional iron overload in myelodysplastic syndrome or Diamond Blackfan anemia

OpenPayer

Chelating Agents - Iron Chelators (Oral) Preferred Specialty Management Policy

Coverage Criteria for Non-Preferred Oral Iron Chelators

Clinical Thresholds and Coding-relevant Criteria

Provider Requirements, Prior Authorization, and Denial Triggers

Background on Oral Iron Chelators

Drug Definitions and Indications